Restart Life Sciences' Wholly Owned Subsidiary Holy Crap Foods Reports over 500,000 Units Sold, Highlighting Strong Consumer Adoption
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that its wholly owned subsidiary, Holy Crap Foods Inc. ("Holy Crap"), has surpassed 500,000 units sold from January 2023 through March 2026. This milestone reflects continued consumer adoption, repeat purchasing behavior, and steady brand development within the "better-for-you" food category. The C
Technology, Biotechnology, Health
2026-04-23 8:00 AM EDT | Restart Life Sciences Corp.
Psyched Wellness Highlights U.S. Federal Policy Momentum Supporting Psychedelic Sector
Toronto, Ontario--(Newsfile Corp. - April 23, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company"), a life sciences company focused on the production and distribution of Amanita Muscaria-derived health and wellness products, today highlights recent U.S. federal policy developments supporting psychedelic research and outlines the potential implications for the sector and the Company. Recent announcements by U.S. President Donald Trump include an exec
Cannabis, Health, Psychedelics, Cannabis Manufacturer
2026-04-23 7:30 AM EDT | Psyched Wellness Ltd.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - April 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will provide an overview of the Company's INTASYL siRNA platform and discuss recent clinical progress and priorities,
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-04-23 7:00 AM EDT | Phio Pharmaceuticals Corp.
Optimi Health Files LIFE Offering Document in Connection with NASDAQ Listing
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced that further to its press release dated March 16, 2026, it intends to complete a portion of its previously announced offering of common shares (the "Offering") in Canada pursuant to the Listed Issuer Financing Exemption c
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-04-23 7:00 AM EDT | Optimi Health Corp.
Delivra Health Brands Enters into Licence Agreement with Peak Processing to Manufacture and Distribute Its Topical Brand LivRelief Infused(TM)
Vancouver, British Columbia--(Newsfile Corp. - April 22, 2026) - Delivra Health Brands Inc. (TSXV: DHB) OTCQB: DHBUF) ("Delivra Health" or the "Company"), a consumer packaged goods company uniquely positioned in the health and wellness sector, announced today that its wholly-owned subsidiary, LivCorp Inc., has entered into a licence agreement ("Licence Agreement") with Peak Processing Solutions ("Peak") (ASX: PKP), to manufacture, distribute and sell infu
Cannabis, Health, Cannabis Extractor, Cannabis Manufacturer
2026-04-22 5:45 PM EDT | Delivra Health Brands Inc.
Promino Provides Update Respecting Private Placement
Burlington, Ontario--(Newsfile Corp. - April 22, 2026) - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTCID: MUSLF) (FSE: 93X) ("Promino" or the "Company") announces, further to its news release dated March 13, 2026, that it is progressing towards completion of a non-brokered private placement (the "Offering") for up to $1,200,000 in gross proceeds, through the issuance of up to 40,000,000 units of the Company ("Units") at a price of $0.03 per Unit. Each Unit wil
Food / Beverages, Sports, Health
2026-04-22 5:13 PM EDT | Promino Nutritional Sciences, Inc.
Unbuzzd Wellness Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant
Vancouver, British Columbia--(Newsfile Corp. - April 22, 2026) - Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzdTM ("unbuzzd") — the scientifically-proven and game-changing beverage proven to accelerate alcohol metabolism, restore mental clarity and reduce hangover symptoms, is pleased to announce the appointment of Mr. Richard Buzbuzian as Chief Executive Officer. This marks a pivotal milestone in the Company's commer
2026-04-22 9:01 AM EDT | Unbuzzd Wellness Inc.
Adia Nutrition, Inc. Looking to Acquire Larger Property to Expand Flagship Clinic in Winter Park, Reports Strong Operational Momentum in Q1 2026 and Provides Optimistic Outlook for Remainder of the Year
Winter Park, Florida--(Newsfile Corp. - April 22, 2026) - Adia Nutrition, Inc. (OTCQB: ADIA), a leader in regenerative medicine, stem cell therapies, and biologic products through its Adia Med clinics and Adia Labs division, today announced that it is actively looking to acquire a larger property to expand its flagship Adia Med clinic in Winter Park, Florida. This strategic initiative aims to significantly increase the clinic's size and capacity, enabling expanded patient access to advanced r
Healthcare and Hospitals, Health
2026-04-22 8:00 AM EDT | Adia Nutrition Inc.
Functional Brands Inc. Enters Strategic Partnership with partnrup.ai to Accelerate Growth of Tru2u.health
Lake Oswego, Oregon--(Newsfile Corp. - April 22, 2026) - Functional Brands Inc. (NASDAQ: MEHA), a leading innovator in wellness and performance products, today announced a strategic technology partnership with partnrup.ai, a next-generation artificial intelligence platform purpose-built to support and improve partner-driven customer acquisition. The partnership will deploy partnrup.ai's full technology stack on behalf of Tru2u.health, a digital health platform dedicated to helping individuals
Household / Consumer / Cosmetics, Health
2026-04-22 8:00 AM EDT | Functional Brands Inc.
Restart Life Sciences Provides Performance and Revenue Trend Update on Newly Acquired Superseed Cereals and Oatmeal Brand Portfolio
Vancouver, British Columbia--(Newsfile Corp. - April 22, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to provide an operational update on its wholly owned subsidiary following the successful completion of its acquisition of Holy Crap Foods Inc. Since the closing of the transaction on February 27, 2026, Restart has been transitioning ownership and integrating portfolio operations under its leadership. The Compa
Technology, Biotechnology, Health
2026-04-22 6:00 AM EDT | Restart Life Sciences Corp.
PreveCeutical Announces Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - April 22, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce a non-brokered private placement (the "Offering") of up to 40,000,000 units (each, a "Unit") in the capital of the Company at a price of $0.
Biotechnology, Pharmaceuticals, Health
2026-04-22 3:00 AM EDT | PreveCeutical Medical Inc.
DiagnosTear Technologies Inc. Announces Adoption of Semi-Annual Reporting
Vancouver, British Columbia--(Newsfile Corp. - April 21, 2026) - DiagnosTear Technologies Inc. ("DiagnosTear" or the "Company") announces that it has adopted a semi-annual financial reporting ("SAR") framework, effective immediately. This change is being made pursuant to British Columbia Securities Commission Coordinated Blanket Order 51-933 Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers ("CBO 51-933"). CBO 51-933 allows eligible
2026-04-21 5:00 PM EDT | DiagnosTear Technologies Inc.
TelyRx Announces Year-End 2025 Financial Results
Clearwater, Florida--(Newsfile Corp. - April 21, 2026) - TelyRx Holdings Inc. (TSX: TELY) ("TelyRx" or the "Company"), a vertically integrated, technology-enabled healthcare and pharmacy services company, today filed audited financial statements for TelyRx, Inc., its wholly-owned subsidiary and reverse takeover acquirer, on SEDAR+ for the year ended December 31, 2025. All dollar amounts are expressed in U.S. dollars. Highlights for the Year and Fourth Quarter of 2025
Healthcare and Hospitals, Health
2026-04-21 4:49 PM EDT | TelyRx
Izotropic Announces Debt Settlement
British Columbia and Sacramento, California--(Newsfile Corp. - April 21, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it has entered into a debt settlement agreement (the "Agreement") with a lender (the "Le
2026-04-21 2:09 PM EDT | Izotropic Corporation
Microbiome Labs relaunches BiomeFX to advance gut microbiome interpretation
Franklinton, North Carolina--(Newsfile Corp. - April 21, 2026) - Microbiome Labs™, a leader in microbiome-based solutions, today announced the relaunch of its BiomeFX™ Functional Microbiome Analysis in partnership with Jona, the AI-powered gut microbiome company. The interpretation layer of BiomeFX is now powered by Jona AI, a clinical-grade microbiome anal
2026-04-21 9:00 AM EDT | Microbiome Labs
Gregory Esemplare Appointed Chief Operating Officer of HarmonyRx
New York, New York--(Newsfile Corp. - April 21, 2026) - HarmonyRx today announced the appointment of Gregory Esemplare as Chief Operating Officer (COO). In this role, Greg will oversee operations across the organization, with a focus on driving alignment, enhancing execution and supporting continued growth in pharmacy benefits. Greg brings extensive experience in healthcare services, pharmacy benefits and client-focused operations. He previously served in a senior le
2026-04-21 8:25 AM EDT | HarmonyRx
WELL Health Reports Record Canadian Patient Visits and Primary Care Margin Expansion in Q1-2026
WELL Canada delivered a record ~1.27 million patient visits(1) in Q1-2026, representing 33% year-over-year growth and 13% organic growth, reflecting broad-based strength across its national network. Primary Care Adjusted EBITDA(2) margins expanded to approximately 8% in Q1-2026 on a preliminary basis, up approximately 200 basis points from 6% in Q1-2025, driven by WELL's clinic transformation program and re
Technology, Computer Software, Healthcare and Hospitals, Health
2026-04-21 7:00 AM EDT | WELL Health Technologies Corp.
The Longevity Investors Conference Announces 2026 Speaker Lineup Featuring Dave Asprey, Dr. Steve Horvath, Garri Zmudze and More
Zug, Switzerland--(Newsfile Corp. - April 20, 2026) - The Longevity Investors Conference (LIC), the world's most private gathering at the intersection of longevity science and capital, returns for its seventh annual edition, taking place September 14-17, 2026 at Le Grand Bellevue in Gstaad, Switzerland. With a 20% acceptance rate, a place at LIC is among the most sought-after in the longevity investment world - and Early Bird pricing closes May 31.
2026-04-20 1:55 PM EDT | Longevity Investors AG
LevelJump Closes Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - April 20, 2026) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company"), is pleased to announce that, further to its news release of April 7, 2026, it has closed, effective as of April 16, 2026, a non-brokered private placement (the "Offering") through the issuance of 14,380,000 common shares (the "Offered Shares") at a price of C$0.05 per Offered Share in the capital of the Company for gross proceeds of C$719,000. All sec
Healthcare and Hospitals, Health
2026-04-20 12:12 PM EDT | LevelJump Healthcare Corp.
Nualtis Corp. Announces Participation in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Montreal, Quebec--(Newsfile Corp. - April 20, 2026) - Nualtis Corp., a specialty pharmaceutical company focused on the development of innovative oral dissolvable film (ODF) drug delivery technologies, will be participating in the 2026 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 21 and 22 at the Metro Toronto Convention Centre.
Technology, Biotechnology, Investment Banking, Health
2026-04-20 11:41 AM EDT | Bloom Burton & Co. Inc.